Effect of GLP1 Receptor Agonists on Physical Function, Body Composition, and Markers of Aging in Older Adults

The University of Texas System (UT)

Status and phase: Completed; Phase 4

Conditions: Aging; Overweight and Obesity; Diabetes Mellitus, Type 2; PreDiabetes

Treatments: Behavioral: Lifestyle Counseling; Drug: Semaglutide Injectable Product

Study type: Interventional

Funder types: Other; NIH

Identifiers

NCT05786521

20220256HU

5P30AG044271-08 (U.S. NIH Grant/Contract)

Details and patient eligibility

About

Semaglutide is a medication approved by the US Food and Drug Administration (FDA) as an antihyperglycemic (a drug that reduces glucoses in those with diabetes) and for weight management. This new study will help find out what effects, semaglutide has on people who take the drug and the drug's effect on physical function, body composition, and aging.

Enrollment: 20 patients

Sex: All

Ages: 65 to 90 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Older than 65
• Have prediabetes or diabetes
• BMI ≥ 27.0 kg/m2
• Living independently (not in assisted living or nursing home)

Exclusion criteria

• Have heart disease
• Have liver disease
• Smoke

Trial design

Primary purpose: Basic Science

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

20 participants in 2 patient groups

Semaglutide and lifestyle intervention

Experimental group

Description:

Participants will meet with a dietician throughout the study to discuss lifestyle counseling based on recommendation in the diabetes prevention program. They will also be given semaglutide for 20 weeks.

Treatment:

Drug: Semaglutide Injectable Product

Behavioral: Lifestyle Counseling

Lifestyle intervention

Active Comparator group

Description:

Participants will meet with a dietician throughout the study to discuss lifestyle counseling based on recommendation in the diabetes prevention program

Treatment:

Behavioral: Lifestyle Counseling